BVNKF News and Press, Bavarian Nordic R/I Ord From 02/23/24

Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company...

2024-02-21 15:09:19 ET More on Bavarian Nordic A/S Historical earnings data for Bavarian Nordic A/S Financial information for Bavarian Nordic A/S Read the full article on Seeking Alpha For further details see: Bavarian Nordic pulls plug on cancer vaccine ...

2023-11-16 13:13:08 ET Bavarian Nordic A/S (BVNKF) Q3 2023 Earnings Call Transcript November 16, 2023 08:00 AM ET Company Participants Rolf Sass Sorensen - Vice President of Investor Relations Paul Chaplin - President and Chief Executive Officer Henrik Juuel - Ex...

2023-09-01 12:45:33 ET More on Bavarian Nordic Bavarian Nordic A/S ( OTCPK:BVNKF ) Q2 2023 Earnings Call Transcript Bavarian Nordic receives $120m contract for manufacturing of smallpox and mpox vaccine from U.S. government Bavarian Nordic monkeypox vaccine Jynne...

2023-08-23 13:42:08 ET Bavarian Nordic A/S (BVNKF) Q2 2023 Earnings Conference Call August 23, 2023 8:00 AM ET Company Participants Rolf Sass Sorensen - Vice President Investor Relations Paul Chaplin - President and Chief Executive Officer Jean-Christophe May - E...

2023-08-23 12:03:27 ET Bavarian Nordic A/S press release ( OTCPK:BVNKF ): 1H net gain of DKK 914 million Revenue increased by 278% Y/Y to DKK 3,239 million. For further details see: Bavarian Nordic A/S reports 1H results

Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22 days post a single vaccination. A fast and durable response was confirmed with high levels of immunity at both 2 weeks and 6 months post a ...

Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022 Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines Company upgrades its financial guidance for 2023 COPENHAGEN, Denmark, August 3,...

Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third quarter of 2023 COPENHAGEN, Denmark, June 27, 2023 – Bavarian Nordic A/S (OMX: BA...

Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity resu...